
AnaMar AB is developing a first-in-class, anti-fibrotic medicine to prevent, slow and heal scarring caused by fibrosis through its patented suite of serotonin (5-HT2B) receptor antagonists. Our selective, oral 5-HT2B receptor antagonist, AM1476, has broad therapeutic potential across fibrotic conditions, which affect millions of patients but have limited, if any, treatment options, including systemic fibrotic disorders and organ-specific fibrotic disorders such as interstitial lung diseases. AM1476 performed successfully in in vitro and in vivo models of fibrosis, as well as demonstrating…
Annual Revenue$1M to $5MBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more

Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.